GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
The purpose of this study is to assess the efficacy and safety of itacitinib in combination with corticosteroids as first-line treatment for moderate or severe chronic graft-versus-host disease (cGVHD).
Inclusion Criteria:
Exclusion Criteria:
Little Rock, Arkansas 72205, United States
La Jolla, California 92093, United States
Park Ridge, Illinois 60028, United States
Indianapolis, Indiana 46202-5201, United States
Munich, 81675, Germany
Petach Tiqwa, 49100, Israel
Bologna, 40138, Italy
Milan, 20132, Italy
Roma, 00161, Italy
Gliwice, 44-101, Poland